Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective ...

Shares of Pfizer Inc. PFE slid 2.18% to $23.29 Thursday, on what proved to be an all-around dismal trading session for the ...

President Trump urges top pharmaceutical firms to lower U.S. drug prices under his most-favored-nation drug pricing policy ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe ...

Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment.

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

The American multinational biotech firm developed a form of santonin used to treat intestinal worms, which gained rapid ...

Disclosure: None. This article is originally published at Insider Monkey.

On July 30, 2025, Pfizer (PFE) saw its shares drop by 2.02%, with a trading volume hitting $0.86 billion and ranking 118th in ...

Income-focused investors actively pursuing high yielders should understand what they stand to sacrifice by reaching for a ...